What not to build is usually the harder decision.
Pharmaceutical digital product strategy for companies deciding what to build before a budget is committed: which properties are worth having, which should be retired, and where a small investment would outperform a large one.
Companies rarely lack digital properties, they lack a reason to keep half of them. A strategy engagement exists to answer, with evidence rather than opinion, what should be built, what should be merged, and what should simply be shut down.
An audit of the current digital estate, a prioritised roadmap, business cases for the initiatives worth funding, and a recommendation on sequencing that respects what your team can actually deliver in a year.
The engagement ends with a roadmap scoped ready to build, by us or by whoever you choose, rather than a strategy document that sits in a drive.
The scale pharmaceutical digital product strategy work has had to evaluate in our engagements.
The trigger differs by company. Pharmaceutical digital product strategy starts from what prompted the question.
What comes up before commissioning a strategy engagement.
No. The roadmap is scoped so it can be delivered by whoever the client chooses to build it, including another agency or an internal team entirely. Where the recommendation is not to build anything at all, or to reduce scope rather than expand it, we say that clearly too.
It scales with the size of the estate being reviewed. A single-market laboratory with two properties is a much shorter engagement than a group with affiliates across a dozen countries, and we scope the timeline to match rather than applying a fixed template.
For a digital roadmap specifically, generally yes. For broader commercial or organisational strategy that happens to touch digital, a specialist consultancy may be the better fit, and we would say so rather than stretching the engagement beyond what it should cover.
Then that is the recommendation we give, unfiltered. Retiring a property that costs more to maintain than it ever returns is frequently the highest-value outcome of this kind of work, even though it is usually the one stakeholders find hardest to hear and act on.
Strategy work usually leads into scoping and then a build. These are the services the roadmap tends to point at.
A budget without an agreed priority, or an estate that has grown without a plan. Tell us the situation and we will tell you how we would approach the pharmaceutical digital product strategy.